Previous 10 | Next 10 |
Gainers: Idera Pharmaceuticals (IDRA) +22%, Beyond Air (XAIR) +14%, Clover Health Investments (CLOV) +14%, Adial Pharmaceuticals (ADIL) +13%, CollPlant Biotechnologies (CLGN) +10%.Losers: Mereo BioPharma (MREO) -9%, Portage Biotech (PRTG) -9%, ...
Hopes were high for Orphazyme’s arimoclomol following FDA’s controversial decision on Alzheimer’s therapy aducanumab. However, the agency has rejected arimoclomol, and the company released weak guidance for 2021. Orphazyme needs to tap the equity markets relat...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In another one of the wild (and arguably unpredictable) adventures of coordinated trading on Reddit , biotechnology firm Orphazyme (NASDAQ: ORPH ) recently produced more gyrations on its technical chart than robust s...
Ole Schwander/iStock via Getty Images Orphazyme cut to sell at Guggenheim after regulatory snub Orphazyme (ORPH) is trading ~3.4% higher in the pre-market today after losing more than 50% on Friday in reaction to its failure to win FDA approval for arimoclomol. With a $1.00 pri...
Shares of Denmark-based biopharmaceutical company Orphazyme’s (ORPH) experienced extreme volatility this month due to the actions of retail traders that were triggered by discussions about the stock on social media platforms such as Reddit. After hitting its $4.75 all-time low on June ...
A lot of everyday investors recently lost a bundle betting that the Food and Drug Administration would approve an experimental drug from Orphazyme (NASDAQ: ORPH) . There were reasons to suspect arimoclomol might earn approval to treat a rare life-threatening disease. There were also...
Investing in Penny Stocks in Summer 2021 Penny stocks are some of the hottest commodities of the year. With massive rises in value in only a short time frame and low prices, penny stocks remain popular among all types of investors. While these stocks have gotten a bad rap over the p...
Gainers: Geron (GERN) +48%.CAI International (CAI) +46%.Sykes Enterprises (SYKE) +30%.PDS Biotechnology (PDSB) +18%.Smith & Wesson Brands (SWBI) +17%.Biophytis (BPTS) +13%.SemiLEDs (LEDS) +10%.Clean Energy Fuels (CLNE) +10%.Luokung Technology (LKCO) +10%.Vinco Ventures (BBIG) +9%.Los...
Shares of Orphazyme (NASDAQ: ORPH) , a clinical-stage biopharmaceutical company, are getting hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved ...
JHVEPhoto/iStock Editorial via Getty Images Danish biotech Orphazyme ([[ORPH]] -43.0%) has extended the pre-market losses after the FDA decision not to grant the approval for Arimoclomol the company’s experimental therapy for rare genetic disease Niemann-Pick Disease Type C ((NPC)). Cy...
News, Short Squeeze, Breakout and More Instantly...
Orphazyme A/S Company Name:
ORPH Stock Symbol:
NASDAQ Market:
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan discusses the company's record-breaking financial results in 2023 in an interview with Proactive's Stephen Gunnion. hVIVO announced a 16% year-on-year growth in revenue, reaching £56 million, with an EBITDA margin i...
(NewsDirect) hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions whil...
(NewsDirect) hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candid...